HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rubio, M.-T. Articles by Sykes, M. Search for Related Content PubMed PubMed Citation Articles by Rubio, M.-T. Articles by Sykes, M.

Mechanisms of the Antitumor Responses and Host-versus-Graft Reactions Induced by Recipient Leukocyte Infusions in Mixed Chimeras Prepared with Nonmyeloablative Conditioning: A Critical Role for Recipient CD4⁺ T Cells and Recipient Leukocyte Infusion-Derived IFN--Producing CD8⁺ T Cells¹

Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129

Surprisingly, antitumor responses can occur in patients who reject donor grafts following nonmyeloablative hemopoietic cell transplantation. In murine mixed chimeras prepared with nonmyeloablative conditioning, we previously showed that recipient leukocyte infusions (RLI) induced loss of donor chimerism, IFN- production, and antitumor responses against host-type tumors. However, the mechanisms behind this phenomenon remain to be determined. We now demonstrate that the effects of RLI are mediated by distinct and complex mechanisms. Donor marrow rejection is induced by RLI-derived alloactivated T cells, which activate non-RLI-derived, recipient IFN--producing cells. RLI-derived CD8 T cells induce the production of IFN- by both RLI and non-RLI-derived recipient cells. The antitumor responses of RLI involve mainly RLI-derived IFN--producing CD8 T cells and recipient-derived CD4 T cells and do not involve donor T cells. The pathways of donor marrow and tumor rejection lead to the development of tumor-specific cell-mediated cytotoxic responses that are not due to bystander killing by alloreactive T cells.

This article has been cited by other articles:

				Y. Kamiryo, M. Eto, H. Yamada, T. Yajima, M. Harano, A. Takeuchi, K. Tatsugami, M. Hamaguchi, S. Naito, and Y. Yoshikai Donor CD4 T Cells Are Critical in Allogeneic Stem Cell Transplantation against Murine Solid Tumor Cancer Res., June 15, 2009; 69(12): 5151 - 5158. [Abstract] [Full Text] [PDF]

				T. I. Saito and M. Sykes NK1.1+ Cells Are Involved in the Anti-Tumor Immunity Induced by the Rejection of Donor Hematopoietic Cells in Mixed Bone Marrow Chimeras. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 3166 - 3166. [Abstract] [PDF]

				T. I. Saito and M. Sykes Long-Lasting Anti-Tumor Immunity Induced by the Rejection of Donor Hematopoietic Cells in Mixed Bone Marrow Chimeras. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 1319 - 1319. [Abstract]

				T. R. Spitzer Haploidentical Stem Cell Transplantation: The Always Present but Overlooked Donor Hematology, January 1, 2005; 2005(1): 390 - 395. [Abstract] [Full Text] [PDF]